Québec, Quebec, Canada
NCT Number: NCT00801788
Single Dose Pharmacokinetics of Egalet® Oxycodone
The purpose of the study is to evaluate the pharmacokinetic profile of different Egalet® oxycodone formulations and compare to a marketed oxycodone product.
Looking for future studies?
Notify MeKey information
Conditions
Age range
18 year–55 year
Sex eligibility
All sexes
Study type
Interventional
Phase
Phase 1
Primary location
Who can participate
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Main inclusion criteria:
- ≥18 years and ≤55 years
- Non-smoker
- BMI ≥18.0 and ≤30.0
Main exclusion criteria:
- Any clinically significant abnormality or abnormal laboratory test results found during medical screening
- History of allergic reactions to opioids or other related drugs
- History of significant alcohol abuse or drug abuse
- Use of any drugs known to inhibit hepatic drug metabolism
- Pregnant or breast-feeding
Treatment and study plan
Oxycodone hydrochloride
DrugExtended release tablet
Primary outcomes
-
To evaluate pharmacokinetics of Egalet® oxycodone. AUC0-t, AUC0-inf, Cmax, Residual Area, Tmax, T½ el,Kel,AUC 0-12 and AUC 0-24.
Time frame: Single-dose evaluation
Secondary outcomes
-
To evaluate safety and tolerability of Egalet® oxycodone. Hematology, biochemistry, urinalysis, vital signs (including pulse oximetry), and adverse event monitoring.
Time frame: Single-dose evaluation
Sponsors and collaborators
Lead sponsor
Egalet Ltd
Industry
Registry information
Important dates
- Study start
- 2008
- Primary completion
- 2008
- Study completion
- 2009
- First posted
- Dec 4, 2008
- Registry last updated
- Aug 29, 2016
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Virtual Reality Intervention in Children After Hypospadias Surgery
NCT07752680
Comfort, Congenital Abnormalities
Istanbul, Beykoz, Turkey (Türkiye)
View Trial DetailsBreakthrough Pain Computer Integrated Patient Controlled Epidural Analgesia
NCT02313571
Neurologic Manifestations, Pain
Singapore
View Trial DetailsChronic Pain Dynamic Psychophysical Tests and Genetic Screening
NCT02373696
Neurologic Manifestations, Pain
Singapore
View Trial DetailsPatient Controlled Administration of Liquid Acetaminophen
NCT06498713
Agnosia, Nervous System Diseases
New Haven, Connecticut, United States
View Trial Details